
Opinion|Videos|November 9, 2023
KEYNOTE-522: Pembrolizumab in Triple-Negative Breast Cancer
Erika P. Hamilton, MD, and the Oncology Brothers offer clinical insights on recent data from KEYNOTE-522 on pembrolizumab in patients with triple-negative breast cancer.
Advertisement
Advertisement
Related to this article

In HypoMast-IMNI, 16-fraction radiotherapy was noninferior to 25 fractions for locoregional recurrence after mastectomy in high-risk breast cancer.

Five-year PHERGain results support PET-guided treatment de-escalation in HER2-positive breast cancer, with ctDNA offering insight into recurrence risk

The FDA approved the oral SERD giredestrant with everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer based on phase 3 evERA data.
Advertisement
Advertisement
Trending on Targeted Onc
1
Daraxonrasib Plus Chemo Yields Durable Response in First-Line PDAC
2
PET-Guided Strategy May Spare Chemotherapy in HER2-Positive Breast Cancer
3
Treatment Sequencing and Toxicity Are Top Concerns in HER2-Mutant NSCLC
4
Galinpepimut-S Improves Overall Survival in Phase 3 REGAL Trial in AML
5
